TABLE 1.
Studies Selected for Evaluations using CDA RWE Submission Guidelines.
| Name of the drug (date of publication) | PSP program | Disease indicated | Size of patient population (N) | Effectiveness measured |
|---|---|---|---|---|
|
a
Infliximab (Remicade) [12] Feb 2025 |
BioAdvance | Inflammatory Bowel Diseases | 13203 | Persistence after Therapeutic Drug Monitoring and dose optimization |
|
a
Videolizumab (Entyvio) [13] March 2024 |
OnePath | Inflammatory Bowel Diseases | 436 | Relation between drug concentration and symptoms |
|
a
Mepolizuman (Nucala) [14] Feb 2024 |
MYNUCALA | Asthma | 275 | Treatment outcomes compared between beginning to end of treatment |
|
a
Brodalumab (Siliq) [14] April 2023 |
SILIQ patient support program | Plaque Psoriasis | 864 | Clinical symptoms improvement and persistence |
| Ustekinumab (Stelara) [16] July 2023 |
BioAdvance | Inflammatory Bowel Disease | 8724 | Treatment Persistence |
| Ixekizumab (Taltz) [17] July 2023 |
LillyPlus Support Services | Plaque Psoriasis | 1891 | Treatment persistence |
| Tofacitinib (Xeljanz) [18] Feb 2023 |
eXel | Rheumatoid Arthritis | 4276 | Treatment pattern and persistence |
| Dimenthyl Fumarate (Tecfidera) [19], April 2022 | Biogen ONE | Multiple Sclerosis | 12608 | Treatment adherence and persistence |
| Erenumab (Aimovig) [20] August 2021 |
Go Program | Migraine | 14,282 | Treatment persistence |
a
Studies grouped under Interventional (outcome based).